FushenShaMD

Hospitalist

Dr. Sha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Fushen Sha is an internal medicine specialist based in Kennewick, WA. He completed his residency in internal medicine from 2020 to 2023 at SUNY Downstate Health Sciences University, after graduating in 2019 from Sun Yat-Sen University of Medical Science. During his residency, he worked at SUNY Downstate Medical Center, Memorial Sloan Kettering Cancer Center, and NYC H+H/Kings County Hospital Center. Dr. Sha has co-authored several research papers, with publications on topics such as follicular lymphoma, neoadjuvant anti-PD-1/PD-L1 therapies, and COVID-19 treatments and vaccines. His work has been recognized and cited in the academic community.

SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2020 - 2023
Sun Yat-Sen University of Medical ScienceClass of 2019

PubMed

Journal Articles

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD..., Blood Cancer J, 5/20/2019
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A, Haematologica, 4/2019
miR-183 potentially inhibits NF-κB1 expression by directly targeting its 3'-untranslated region
Sha F, Wu S, Zhang H, Guo X, Acta Biochim Biophys Sin, 10/1/2014

Books/Book Chapters

Chinese Guidelines on the Diagnosis and Treatment of Lymphoma
Chapter: Diagnosis and Treatment of Hodgkin's Lymphoma
Page 110 - 120Ma J, Shuang Y, Wu G, Zhu J, Zhu H, Li Z, Qiu L, Shen L, Su L, Chen J, Zhou J, Yi P, Lin T, Lin S, Jin J, Xu B, Gu K, Gao Z, Huang H, Bao H, Wang Z, Fang X, Sha F*, Re...Editors: In Ye Y, Wang M, Long H.China Medical TribuneEdition 2017,2017

Abstracts/Posters

Impact of PET Imaging and Histological Transformation on the Prognosis of Early Disease Progression in Follicular Lymphoma
Batlevi CL, Sha F*, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano J, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz G, Noy A, Palomba M, Portlock C,..., International Conference on Malignant Lymphoma (ICML), Lugano, CHE, 6/2019
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II...
Lin T, Sha F, Huang H, Wang Z, Lin S, Li X, Hong X, Fang X, Li F,Peng C, Ren Q, Zhang L, Liu Q, American Society of Clinical Oncology, Chicago, IL, 6/2018
Randomized, open-label, phase II trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lym...
Huang H, Li X, Hong H, Wang Z, Fang X, Li F, Peng C, Ren Q, Sha F*, Zhang L, Lin S, Liu Q, Lin T, American Society of Clinical Oncology, Chicago,IL, 1949